Company intelligence / Profile preview

Alphalyse

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

Alphalyse is recognized as the global leader in mass spectrometry-based host cell protein (HCP) analysis and advanced protein characterization. Their methods have been incorporated into US Pharmacopeia guidelines and accepted by regulatory agencies including FDA and EMA for GMP release testing. They have enabled several firsts in regulatory acceptance of LC-MS/MS data for INDs and product releases

Modalities: Monoclonal antibodyRecombinant proteinVaccineCell therapyGene therapy
Industry: Drug Discovery Services

Partnerships

Collaborations with University of Southern DenmarkInstrument companies in mass spectrometry field

Beyond the preview

Go deeper on Alphalyse.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alphalyse.

Explore the full profile